Improving Maternal Nutrition in Matlab (IMNiM)
27 avril 2021 mis à jour par: International Centre for Diarrhoeal Disease Research, Bangladesh
In-home, Intensive Nutrition Counseling to Improve Gestational Weight Gain in Rural Bangladesh: A Cluster-Randomized Controlled Trial
Background: Maternal undernutrition and inadequate gestational weight gain (GWG) are prevalent in rural communities of low- and middle-income countries (LMICs). In Matlab, Bangladesh, 54% of the women fail to gain adequate weight (>4 kg) in the third trimester. Risks associated with inadequate GWG include giving birth to a small-for-gestational age (SGA) infant, low birth weight (LBW) infant, preterm birth (PTB), etc. Few contemporary studies examined the efficacy of nutrition counseling on GWG improvement in LMICs.
Objectives: The primary objective of this study is to assess whether in-home, intensive nutrition counseling during pregnancy, compared to standard antenatal care, could improve GWG among pregnant women in rural Bangladesh.
Methods: This prospective, two-arm, parallel group, equal allocation, open-label, community-based, cluster-randomized controlled trial will be conducted in the icddr,b service area of Matlab, a rural subdistrict of Bangladesh. Clusters will be randomly allocated 1:1 to the intervention arm in which pregnant women will receive monthly in-home, intensive nutrition counseling or the control arm in which pregnant women will receive standard antenatal care as offered by icddr,b and Govt. facilities. Fixed Site Clinics (FSCs) located at the homes of the community health research workers (CHRWs) will act as clusters. Of the 33 FSCs serving rural areas in the icddr,b service area, 20 will be selected randomly and listed. These 20 clinics will then be randomly allocated 1:1 to either an intervention or control group using a computer-generated random allocation sequence. To fulfil the required sample size, each selected CHRW will enroll 16 consecutive pregnancies. Required sample size is 16 women per cluster i.e. 160 women per arm. Eligible participants will be enrolled upon obtaining their consent by 13 and 6/7 weeks of gestation (first trimester) and followed up to 6 weeks postpartum. Trained health workers will visit the homes of the women in the intervention arm once a month and provide nutrition counseling to the women and her influential family members such as mothers, mothers-in-law and husbands. Both intention-to-treat and per-protocol analyses will be performed.
Outcome measures/variables: Proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to the US Institute of Medicine (IOM) 2009 guidelines is the primary outcome variable.
Aperçu de l'étude
Statut
Actif, ne recrute pas
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
287
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Chandpur, Bengladesh
- International Centre for Diarrhoeal Disease Research, Bangladesh
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 39 ans (Adulte)
Accepte les volontaires sains
Oui
Sexes éligibles pour l'étude
Femelle
La description
Pregnant women permanently residing in the icddr,b service area of Matlab fulfilling the following criteria:
Inclusion Criteria:
- aged 18-39 years
- in the first trimester of pregnancy (before 14 weeks of gestation)
- BMI 16-24.99 kg/m^2 measured on enrollment
- willing to participate in the study
Exclusion criteria
- multiple pregnancy (carrying two or more fetuses)
- threatened abortion, persistent pervaginal bleeding, or cervical incompetence
- history of three or more consecutive abortions
- history of gestational diabetes, macrosomia, gestational hypertension, preeclampsia/eclampsia in a prior pregnancy
- chronic diseases, such as hypertension, heart disease, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, pancreatic diseases, Crohn's disease, ulcerative colitis, diabetes mellitus, thyroid dysfunction, immunological diseases, malignancy or any other diseases which could impede compliance with the study protocol
- taking medications known to influence fetal growth, such as insulin, thyroid hormones, glucocorticoids
- known case of serious psychiatric or behavioral disorders, such as schizophrenia, bipolar disorder
- scored as moderate or worse on enrollment on any one of the subscales of the Depression, Anxiety and Stress Scales-21 (DASS-21)
- inability to read or write Bengali
- belonging to moderately or severely food insecure households as measured by the Household Food Insecurity Access Scale (HFIAS)
- having a plan to move or deliver outside the study area
- women practicing some form of vegetarianism
- women belonging to a household from which another woman is already enrolled in the study
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Intervention
In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
|
|
|
Aucune intervention: Control
Pregnant women in this arm will receive standard antenatal care.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to IOM 2009 guidelines
Délai: Pre-delivery
|
Pregnancy trimesters are defined as follows: 1st trimester (0 weeks - 13+6 weeks), 2nd trimester (14 completed weeks - 27+6 weeks), and 3rd trimester (28 completed weeks - childbirth).
Rate of weight gain between two time points (trimesters) will be calculated by subtracting the weight measured at the first time point from the weight measured at the second time point and dividing the derived value by the difference in weeks between the two time points.
|
Pre-delivery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
total gestational weight gain (kg)
Délai: pre-delivery
|
pre-delivery
|
|
|
rate of weight gain during the 2nd and 3rd trimester (kg/week)
Délai: pre-delivery
|
pre-delivery
|
|
|
proportion of women with inadequate total GWG according to IOM criteria
Délai: pre-delivery
|
pre-delivery
|
|
|
proportion of women with inadequate total GWG according to local criteria
Délai: pre-delivery
|
pre-delivery
|
|
|
proportion of women with inadequate third trimester weight gain according to local criteria
Délai: pre-delivery
|
pre-delivery
|
|
|
proportion of preterm births
Délai: at delivery
|
childbirth before 37 completed weeks
|
at delivery
|
|
maternal mid-upper arm circumference (MUAC) (mm)
Délai: baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
|
baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
|
|
|
maternal weight (kg)
Délai: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
|
|
maternal body mass index (BMI) (kg/m^2)
Délai: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
weight and height (at baseline) will be combined to report BMI
|
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
|
infant weight (g)
Délai: at birth (delivery) and after 4 weeks
|
at birth (delivery) and after 4 weeks
|
|
|
infant length (cm)
Délai: at birth (delivery) and after 4 weeks
|
at birth (delivery) and after 4 weeks
|
|
|
infant head circumference (cm)
Délai: at birth (delivery) and after 4 weeks
|
at birth (delivery) and after 4 weeks
|
|
|
proportion of low birth weight (< 2500 g) infants
Délai: at birth (delivery)
|
at birth (delivery)
|
|
|
proportion of small for gestational age (<10th percentile) infants according to Intergrowth-21st standards
Délai: at birth (delivery)
|
at birth (delivery)
|
|
|
proportion of women with pregnancy complications e.g. anemia, preeclampsia
Délai: at delivery
|
at delivery
|
|
|
proportion of women with obstetric complications e.g. induction of labor, caesarean section
Délai: at delivery
|
at delivery
|
|
|
newborn Apgar score
Délai: at birth (delivery)
|
at birth (delivery)
|
|
|
proportion of infants developing morbidity
Délai: 4 weeks after birth
|
4 weeks after birth
|
|
|
proportion of infant mortality
Délai: 4 weeks after birth
|
4 weeks after birth
|
|
|
dietary diversity score according to the "Guidelines for Measuring Household and Individual Dietary Diversity"
Délai: baseline, 36 weeks of gestation and 6 weeks post-partum
|
score range: 0-9; higher scores indicate a better outcome
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
dietary diversity score according to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Délai: baseline, 36 weeks of gestation and 6 weeks post-partum
|
score range: 0-10; higher scores indicate a better outcome
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
proportion of women with inadequate dietary diversity accroding to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Délai: baseline, 36 weeks of gestation and 6 weeks post-partum
|
score range: 0-10; <5 indicates inadequate dietary diversity
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
energy consumption (kcal)
Délai: baseline, 36 weeks of gestation and 6 weeks post-partum
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
|
protein consumption (g)
Délai: baseline, 36 weeks of gestation and 6 weeks post-partum
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
|
proportion of women with symptoms of depression as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Délai: baseline, 36 weeks of gestation and 6 weeks post-partum
|
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms.
Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
proportion of women with symptoms of anxiety as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Délai: baseline, 36 weeks of gestation and 6 weeks post-partum
|
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms.
Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
proportion of women with symptoms of stress as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Délai: baseline, 36 weeks of gestation and 6 weeks post-partum
|
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms.
Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
healthcare seeking and services utilization e.g. number of prenatal visits
Délai: at delivery
|
at delivery
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Collaborateurs
Les enquêteurs
- Chercheur principal: S. M. Tafsir Hasan, MBBS, MS, Nutrition and Clinical Services Division, icddr,b
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
15 janvier 2020
Achèvement primaire (Anticipé)
30 septembre 2021
Achèvement de l'étude (Anticipé)
31 octobre 2021
Dates d'inscription aux études
Première soumission
28 décembre 2019
Première soumission répondant aux critères de contrôle qualité
27 avril 2021
Première publication (Réel)
3 mai 2021
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
3 mai 2021
Dernière mise à jour soumise répondant aux critères de contrôle qualité
27 avril 2021
Dernière vérification
1 avril 2021
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PR-19109
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .